These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2138532)

  • 1. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.
    Talley NJ; Phillips SF; Haddad A; Miller LJ; Twomey C; Zinsmeister AR; MacCarty RL; Ciociola A
    Dig Dis Sci; 1990 Apr; 35(4):477-80. PubMed ID: 2138532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides.
    Talley NJ; Phillips SF; Haddad A; Miller LJ; Twomey C; Zinsmeister AR; Ciociola A
    Dig Dis Sci; 1989 Oct; 34(10):1511-5. PubMed ID: 2529108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
    Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
    Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist.
    Gore S; Gilmore IT; Haigh CG; Brownless SM; Stockdale H; Morris AI
    Aliment Pharmacol Ther; 1990 Apr; 4(2):139-44. PubMed ID: 2151757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.
    von der Ohe MR; Camilleri M; Kvols LK
    Gastroenterology; 1994 May; 106(5):1184-9. PubMed ID: 8174881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans.
    von der Ohe MR; Hanson RB; Camilleri M
    Gut; 1994 Apr; 35(4):536-41. PubMed ID: 8174993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proximal and distal gut hormone secretion in slow transit constipation.
    Penning C; Delemarre JB; Bemelman WA; Biemond I; Lamers CB; Masclee AA
    Eur J Clin Invest; 2000 Aug; 30(8):709-14. PubMed ID: 10964163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
    Houghton LA; Atkinson W; Whorwell PJ; Morris J; Murdoch RD; Cooper SM; Webber DM; Walls CM
    Clin Ther; 2006 Apr; 28(4):569-81. PubMed ID: 16750468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo.
    Gandara DR; Harvey WH; Monaghan GG; Perez EA; Hesketh PJ
    Eur J Cancer; 1993; 29A Suppl 1():S35-8. PubMed ID: 8427724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
    Shin A; Acosta A; Camilleri M; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cholecystokinin octapeptide and atropine on human colonic motility, tone, and transit.
    O'Brien MD; Camilleri M; Thomforde GM; Wiste JA; Hanson RB; Zinsmeister AR
    Dig Dis Sci; 1997 Jan; 42(1):26-33. PubMed ID: 9009112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea.
    Saslow SB; Scolapio JS; Camilleri M; Forstrom LA; Thomforde GM; Burton DD; Rubin J; Pitot HC; Zinsmeister AR
    Gut; 1998 May; 42(5):628-34. PubMed ID: 9659155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luminally released serotonin stimulates colonic motility and accelerates colonic transit in rats.
    Tsukamoto K; Ariga H; Mantyh C; Pappas TN; Yanagi H; Yamamura T; Takahashi T
    Am J Physiol Regul Integr Comp Physiol; 2007 Jul; 293(1):R64-9. PubMed ID: 17442783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascending colon response to feeding: evidence for a 5-hydroxytryptamine-3 mechanism.
    Scolapio JS; Camilleri M; von der Ohe MR; Hanson RB
    Scand J Gastroenterol; 1995 Jun; 30(6):562-7. PubMed ID: 7569764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postprandial gut peptide plasma levels in women with idiopathic slow-transit constipation.
    Peracchi M; Basilisco G; Tagliabue R; Terrani C; Locati A; Bianchi PA; Velio P
    Scand J Gastroenterol; 1999 Jan; 34(1):25-8. PubMed ID: 10048728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of motilin on human interdigestive gastrointestinal and gallbladder motility, and involvement of 5HT3 receptors.
    Luiking YC; Akkermans LM; Peeters TL; Cnossen PJ; Nieuwenhuijs VB; Vanberge -Henegouwen GP
    Neurogastroenterol Motil; 2002 Apr; 14(2):151-9. PubMed ID: 11975715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Closing remarks. Ondansetron: effects on gastrointestinal motility.
    Lamers CB
    Scand J Gastroenterol Suppl; 1991; 188():124-6. PubMed ID: 1837938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.